Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1859-63. doi: 10.1007/s00259-009-1182-1. Epub 2009 Jun 5.

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

Author information

  • 1AstraZeneca R&D, Neuroscience Therapy Area, 151 85 Södertälje, Sweden. svante.nyberg@astrazeneca.com

Abstract

PURPOSE:

Current positron emission tomography (PET) radioligands for detection of Abeta amyloid in Alzheimer's disease (AD) are not ideal for quantification. To improve the signal to noise ratio we have developed the radioligand [(11)C]AZD2184 and report here the first clinical evaluation.

METHODS:

Eight AD patients and four younger control subjects underwent 93-min PET measurements with [(11)C]AZD2184. A ratio approach using the cerebellum as reference region was applied to determine binding parameters.

RESULTS:

Brain uptake of [(11)C]AZD2184 peaked within 1 min at 3-4% of injected radioactivity. AD patients had high radioactivity in cortical regions while controls had uniformly low radioactivity uptake. Specific binding peaked within 30 min at which time standardized uptake value ratios (SUVR) ranged between 1.19 and 2.57.

CONCLUSION:

[(11)C]AZD2184 is a promising radioligand for detailed mapping of Abeta amyloid depositions in Alzheimer's disease, due to low non-specific binding, high signal to background ratio and reversible binding as evident from early peak equilibrium.

PMID:
19495746
[PubMed - indexed for MEDLINE]
PMCID:
PMC2764092
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk